Abstract
Every year, more than 1.5 million people die from lung cancer (LC) worldwide. In a number of industrialized countries, LC is the dominant oncological disease. The beginning of autumn 2022 was marked by a regular landmark event in the professional environment of oncologists: the Annual Congress of the European Society for Medical Oncology (ESMO) was held in Paris. The congress presented and discussed innovative developments in immunotherapy for patients with advanced NSCLC. The purpose of this work was to summarize the current clinical developments in combined immunotherapy for advanced NSCLC discussed at the ESMO Annual Congress – September 2022: IFCT-1701 studies; KEYNOTE-407; KEYNOTE-189; IPSOS; INCREASE. The systematic search for effective antitumor immunodrugs continues, and a comprehensive modernization of the protocols for their use is being carried out. This allows us to hope for a cardinal increase in life expectancy and improvement in its quality in patients with NSCLC, even at the most advanced stages.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: A.I. Burnasyan Federal Medical Biophysical Center Clinical Bulletin
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
